Stéphane Bancel, AP Images

Mod­er­na takes on a low-risk pact with CAR-T play­er Au­to­lus for mR­NA-based can­cer drugs

Mod­er­na’s Covid-19 vac­cine has trans­formed the once-back­wa­ter biotech in­to one of the most high­ly val­ued drug­mak­ers in the world in the span of a year. But what does the fu­ture hold for Mod­er­na’s star turn? A small-scale dis­cov­ery pact could of­fer a clue.

Mod­er­na will hold ex­clu­sive rights to four mR­NA-based im­muno-on­col­o­gy can­di­dates us­ing pro­pri­etary bind­ing tech from Au­to­lus, a biotech best known for its work on “off-the-shelf” CAR-T ther­a­pies, the part­ners said Mon­day.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters